Pharmaceutical enterprises aim at the pharmaceutical prospect of industrial marijuana and lay out 10 billion "emerging industries"

[analysis of China Pharmaceutical network market] since 2019, the concept of industrial marijuana, which once exploded in the US stock market, has been transmitted to the A-share market With the hot financing market and the fierce response of the secondary market, the global industrial marijuana fever looks promising, but in fact, it is not profit but expectation It is reported that many pharmaceutical enterprises are focusing on the future, layout the cultivation and extraction of industrial marijuana What is industrial hemp? Industrial hemp refers to the hemp with THC content lower than 0.3%, which is also called hemp in China Industrial marijuana is widely used in medicine, textile, food, cosmetics, papermaking and other fields Industrial hemp can be described as a treasure of the whole body The downstream application fields of the extracts from its seeds, flower leaves, skin, stem, root and other parts are very wide The hemp seed oil extracted from its seeds can be used in cosmetics, health products, etc.; the hemp phenols extracted from the flower leaves can provide biopharmaceutical raw materials for epilepsy, depression, Parkinson's disease, cancer and other diseases Hemp fiber has the advantages of anti bacteria, air permeability, quick drying, UV protection, etc it can be used as textile or reinforcement materials for building materials, automobiles, aerospace materials, etc It should be reminded that marijuana is a drug and cannot be cultivated At present, Yunnan and Heilongjiang have obtained the legal planting right of industrial marijuana, and Jilin Province is also expected to obtain the legal planting right Analysts pointed out that the application prospect of industrial hemp extract is very broad, and the demand for hemp extract such as cannabis diphenol in the international market is in the ascendant According to statistics, the global cannabis diphenol industry value will reach 5.7 billion US dollars in 2019 and 18.1 billion US dollars in 2021 However, in 2017, the market size of cannabis diphenol industry in China was only 448 million yuan Experts said that there are many market opportunities in the market supply and deep processing of industrial marijuana, especially in the context of the sharp price reduction of drugs, many pharmaceutical enterprises are looking for new business units The author has learned that at present, the pharmaceutical enterprises with industrial marijuana layout include Kangenbei, Zixin pharmaceutical, Longjin pharmaceutical, Tonghua Jinma, etc On March 28, Longjin Pharmaceutical Co., Ltd announced that it plans to increase the capital of Yunnan Muya agricultural science and Technology Co., Ltd by no more than 15 million yuan and obtain 51% equity, the latter's main business is large-scale cultivation of industrial marijuana On March 31, Tonghua Jinma, Jilin Academy of Agricultural Sciences and people's Government of Erdaojiang District of Tonghua City jointly signed the agreement on industrial marijuana cooperation project to explore the breeding, cultivation and product research and development of industrial marijuana In view of the current hot distribution of industrial marijuana in pharmaceutical enterprises, industry insiders said that the layout of domestic pharmaceutical enterprises in this field is still in the early stage According to the data from the National Drug Control Commission, China has never approved the addition of industrial marijuana for medical use and food Only four enterprises have obtained processing licenses, namely, hansu biology, hankang biology, Hansen and baiou biology Not only that, the supervision of industrial marijuana in China is also very strict So far, there are about 30 enterprises with marijuana cultivation license in China, but few enterprises with real qualification of cultivation or processing license It can be said that no matter what the pharmaceutical prospect of industrial marijuana is, there are still many uncertainties in terms of policy for the pharmaceutical enterprises that distribute industrial marijuana On the premise of legalizing marijuana in many countries, the relevant authorities said that China would strengthen the supervision of "industrial marijuana" more strictly, block loopholes in all aspects and improve various management systems As for whether industrial marijuana will become the "right" profit point for pharmaceutical enterprises, professionals said: "there must be opportunities in the existing market At present, the situation that pharmaceutical enterprises have entered in succession is also very normal, just like the merger and acquisition of hospitals by pharmaceutical enterprises in the past few years, it is an attempt to find opportunities Whether it can really become an enterprise and bring new profits depends on whether it can really become an enterprise Subsequent developments "